A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Trial Details

NCT ID

NCT07244341

Phase

PHASE1

Sponsor

Daiichi Sankyo

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• Valemetostat
• Darolutamide

Locations (sample)

• La Jolla, California, United States|32.84727,-117.2742
• Boston, Massachusetts, United States|42.35843,-71.05977
• Newton, Massachusetts, United States|42.33704,-71.20922
• Grand Rapids, Michigan, United States|42.96336,-85.66809
• Lake Success, New York, United States|40.77066,-73.71763

Key Eligibility Criteria

• The clinical site will screen for the full inclusion criteria per protocol.
• Adult males ≥18 years of age at the time the ICF is signed (Please follow local regulatory requirements if the legal age of consent for trial parti…
• Histologically confirmed adenocarcinoma of the prostate. Cases exhibiting neuroendocrine differentiation are eligible for enrollment, except those …
• Evidence of disease progression as per the PCWG3 modified RECIST v1.1 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.